FDA Turns To Epidemiological Data To Resolve Azilect Melanoma Questions
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA used an epidemiological approach to resolve concerns regarding a potentially higher risk of melanoma with Teva’s Parkinson’s disease therapy Azilect, review documents show.